The Hyderabad-based generics maker is now India’s largest supplier of off-patent medicines to the US.
On 3 June, Aurobindo Pharma Ltd announced its annual results. It had turned in a stellar performance, with an all-round improvement in sales and profits. And, on 10 August, its stock raced past Rs 950, the highest level in a decade. But one highlight went almost unnoticed.
In fiscal year 2020, the company’s US sales totted up to $1,622 million, making it the top pharmaceuticals supplier to the lucrative American market and ousting Sun Pharmaceutical Industries Ltd, which notched up $1,487 million, from the top slot.
No small achievement this, considering Aurobindo Pharma’s ascension to the top of the exporters’ …
Surendar helps lead the newsroom at The Morning Context as executive editor. Over the years, Surendar has worked in industries from pharmaceuticals to diamonds, as well as a stint as an equity analyst. In his long career as a business journalist, he has led teams at The Times of India, India Today and Fortune India. He was part of the founding team at Forbes India and interned at and published in The Times, London.
Executive Editor
surendar@mailtmc.com
Mumbai